• Definition: Rapid deterioration in renal function, reflected by:
o ↑ Serum creatinine (≥26 µmol/L within 48 hours or ≥1.5× baseline within 7 days)
o Oliguria: urine output <0.5 mL/kg/hr for >6 hours
• KDIGO Staging (Stages 1–3):
o Stage 1: Cr rise ≥1.5–1.9× baseline or ≥26 µmol/L; urine output <0.5 mL/kg/hr for 6–12 h
o Stage 2: Cr rise 2.0–2.9× baseline; urine output <0.5 mL/kg/hr for ≥12 h
o Stage 3: Cr rise ≥3× baseline or ≥354 µmol/L or initiation of renal replacement therapy;
urine output <0.3 mL/kg/hr for ≥24 h or anuria ≥12 h
o Due to impaired renal perfusion
o Causes: hypovolaemia, hypotension, heart failure, renal artery stenosis
o Often reversible with fluid resuscitation
o Urea:Creatinine ratio ↑, concentrated urine
o Structural damage to kidney parenchyma
o Types:
Acute Tubular Necrosis (ATN)
Acute Interstitial Nephritis (AIN)
Glomerulonephritis (GN)
Vasculitis (e.g. ANCA-associated)
Thrombotic microangiopathy (e.g. HUS, TTP)
o Obstruction of urinary outflow
o Causes: BPH, ureteric stones, tumours, retroperitoneal fibrosis
o Requires imaging (bladder scan, renal US)
o Bilateral obstruction → postrenal AKI
o Commonest intrinsic AKI
o Causes: ischaemia (e.g. shock), toxins (aminoglycosides, contrast)
o Muddy brown granular casts on urine microscopy
o Usually self-limiting but may require dialysis
o Allergic hypersensitivity reaction
o Causes: drugs (e.g. penicillins, NSAIDs, PPIs), infections
o Features: fever, rash, arthralgia, eosinophiluria
o Myoglobin-induced tubular toxicity
o Causes: crush injury, seizures, statins
o ↑ CK, myoglobinuria (dark urine), hyperkalaemia, hypocalcaemia
o Rx: aggressive IV fluids, correct electrolytes
o AKI within 48–72 hours of contrast exposure
o Risk factors: CKD, diabetes, dehydration
o Prevent with IV hydration ± N-acetylcysteine (controversial)
o Rapid cell breakdown (e.g. lymphoma, leukaemia) → ↑ urate, phosphate, K⁺
o Risk: high-grade malignancy, chemotherapy
o Prophylaxis: IV fluids, allopurinol or rasburicase
o Identify and treat underlying cause
o Assess volume status (JVP, BP, urine output)
o Stop nephrotoxins (NSAIDs, ACEi, aminoglycosides)
o IV fluids for hypovolaemia
o Monitor fluid balance, daily weights, U&Es
o Avoid nephrotoxic agents
o Adjust drug doses for renal function
o Acidosis (refractory)
o Electrolyte imbalance (esp. hyperkalaemia)
o Intoxication (certain toxins: lithium, ethylene glycol)
o Overload (fluid, pulmonary oedema)
o Uraemia (encephalopathy, pericarditis)
————————————————————————————————————————————————————————————————————————————————————————————————————————-
Author & Educational Disclaimer
Author:
Dr Phillip Cockrell BM FRCP DipClinEd
Dr Phillip Cockrell is a UK Consultant Physician in Internal Medicine, currently working at Queen Alexandra Hospital, Portsmouth University Hospitals NHS Trust. He has previously worked as a registrar across Intensive Care Medicine, Gastroenterology, Cardiology, Stroke Medicine, Acute Medicine, and Respiratory Medicine.
He has held senior leadership roles including Associate Clinical Director of the Acute Medical Unit, Clinical Director of Internal Medicine, and Chief of Medicine. Dr Cockrell has over 15 years’ experience in postgraduate medical education, having lectured extensively across the MRCP syllabus and contributed to MRCP revision teaching and course development.
Dr Cockrell holds a Bachelor of Medicine (BM), Fellowship of the Royal College of Physicians (FRCP), and a Diploma in Clinical Education (DipClinEd). His teaching approach is based on structured consolidation of complex medical topics to support efficient and effective revision for postgraduate examinations.
Purpose of this content:
The material on this page is intended solely for educational purposes to support revision for the MRCP (UK) Part 1 examination. It reflects examination-relevant principles of internal medicine and is designed to aid learning and pattern recognition.
Medical disclaimer:
This content is designed for postgraduate medical examination revision and does not constitute medical advice, diagnosis, or treatment guidance and must not be used as a substitute for professional clinical judgement, local guidelines, or specialist consultation. Clinical decisions should always be made in the context of individual patient circumstances and current national guidance.